The review found no eligible studies for this question.
Azathioprine showed no clear difference in serious adverse events compared with infliximab (moderate certainty).
Azathioprine + infliximab probably leads to lower serious adverse events compared with infliximab (moderate certainty).
Azathioprine or 6‐mercaptopurine showed no clear difference in serious Adverse events compared with placebo (low certainty).
5‐ASA showed no clear difference in serious adverse events compared with placebo (low certainty).
Ustekinumab showed no clear difference in serious adverse events compared with placebo (moderate certainty).
It is very uncertain whether azathioprine changes serious adverse events compared with budesonide (very low certainty).
It is very uncertain whether azathioprine and infliximab changes serious adverse events compared with infliximab (very low certainty).
It is very uncertain whether 6‐Mercaptopurine changes serious adverse events compared with methotrexate (very low certainty).
It is very uncertain whether azathioprine or 6‐mercaptopurine changes serious adverse events compared with placebo (very low certainty).
It is very uncertain whether azathioprine or 6‐mercaptopurine changes serious adverse events compared with mesalazine or sulfasalazine (very low certainty).
GM‐CSF showed no clear difference in serious adverse events compared with placebo (moderate certainty).
Vedolizumab showed no clear difference in adverse events (6–10 weeks) compared with placebo (moderate certainty).
Vedolizumab showed no clear difference in adverse events (52–60 weeks) compared with placebo (moderate certainty).
The review found no eligible studies for this question.
The review found no eligible studies for this question.
Two infusions of natalizumab (300 mg or 3 mg/kg) showed no clear difference in adverse events up to week 12 compared with placebo (moderate certainty).
Two infusions of natalizumab (6 mg/kg) showed no clear difference in adverse events up to week 12 compared with placebo (moderate certainty).
Three infusions of natalizumab (300 mg) showed no clear difference in adverse events up to week 12 compared with placebo (high certainty).
Three infusions of natalizumab (300 mg) and two infusions of… showed no clear difference in adverse events up to week 10 compared with placebo and two infusions of infliximab (moderate certainty).